{"id":"W2588072385","doi":"10.1093/annonc/mdw379.18","title":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer; GlaxoSmithKline Australia; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Discontinuation; Internal medicine; Nivolumab; Adverse effect; Regimen; Toxicity; Melanoma; Gastroenterology; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005241398,0.0001665084,0.000496896,0.0001746789,0.0001764267,0.0004978065,0.0001586187,0.0002622983,0.001211302],"category_scores_gemma":[0.0009554369,0.0001047252,0.0005457037,0.000226996,0.0001735736,0.0003036492,0.0001340327,0.0008786362,0.0002574597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003746974,"about_ca_system_score_gemma":0.0003152652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002800662,"about_ca_topic_score_gemma":0.0006219338,"domain_scores_codex":[0.9997298,0.0001041926,0.00002384942,0.00004468458,0.00005944275,0.00003802522],"domain_scores_gemma":[0.9996098,0.0001144581,0.000137919,0.00002076935,0.00003714728,0.00007996183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2392459,0.004948556,0.2223306,0.001090957,0.00266527,0.0009939242,0.0003591809,0.003387416,0.05959065,0.0003316148,0.003524268,0.4615317],"study_design_scores_gemma":[0.020878,0.2754727,0.6452258,0.0002497654,0.004471145,0.005461625,0.0004258011,0.007638533,0.01873242,0.0007009986,0.0206558,0.00008737891],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931095,0.004299911,0.0002099843,0.0002021643,0.00004216856,0.0000588693,0.0003858176,0.00001408351,0.001677541],"genre_scores_gemma":[0.9982697,0.0006640421,0.0001038351,0.0001403216,0.00004403952,0.00003081996,0.0002797239,0.000002838194,0.0004646851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001211302,"threshold_uncertainty_score":0.004052281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0230344251180174,"score_gpt":0.3101263806729594,"score_spread":0.287091955554942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}